Immunotherapy for Lewis lung carcinoma utilizing dendritic cells infected with CK19 gene recombinant adenoviral vectors

Oncology Reports
Q F SunX G Zhao

Abstract

Dendritic cells (DCs) as 'professional' antigen-presenting cells (APCs) initiate and regulate immune responses to various antigens. DC-based vaccines have become a promising modality in cancer immunotherapy. Cytokeratin 19 (CK19) protein is expressed at high levels in lung cancer and many other tumor cells, suggesting CK19 as a potential tumor‑specific target for cancer immune therapy. We constructed a recombinant adenoviral vector containing the CK19 gene (rAd-CK19). DCs transfected with rAd-CK19 were used to vaccinate C57BL/6 mice bearing xenografts derived from Lewis lung carcinoma (LLC) cells. The transfected DCs gave rise to potent CK19-specific cytotoxic T lymphocytes (CTLs) capable of lysing LLC cells. Mice immunized with the rAd‑CK19-DCs exhibited significantly attenuated tumor growth (including tumor volume and weight) when compared to the tumor growth of mice immunized with rAd-c DCs or DCs during the 24-day observation period (P<0.05). The results revealed that the mice vaccinated with the rAd-CK19-DCs exhibited a potent protective and therapeutic antitumor immunity to LLC cells in the subcutaneous model along with an inhibitive effect on tumor growth compared to the mice vaccinated with the rAd-c DCs or DCs alone. T...Continue Reading

References

Jul 1, 1997·Nature Medicine·C Nyberg-HoffmanE Aguilar-Cordova
Jun 1, 1997·International Journal of Pancreatology : Official Journal of the International Association of Pancreatology·G OhshioH Sakahara
Apr 1, 1998·Nature·J Banchereau, R M Steinman
Aug 5, 1998·Proceedings of the National Academy of Sciences of the United States of America·R C FieldsJ J Mulé
Mar 23, 2000·International Journal of Cancer. Journal International Du Cancer·J SteitzT Tüting
Apr 25, 2000·Human Gene Therapy·C J Kirk, J J Mulé
Apr 26, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·S SharmaS M Dubinett
Dec 18, 2001·International Journal of Cancer. Journal International Du Cancer·R M Steinman, M Dhodapkar
May 10, 2003·Cancer Immunology, Immunotherapy : CII·George MillerRonald P DeMatteo
May 22, 2004·Cancer Control : Journal of the Moffitt Cancer Center·Robert A Fenstermaker, Michael J Ciesielski
Apr 11, 2007·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Ana López-MartinLuis Paz-Ares
Jan 8, 2008·Brazilian Dental Journal·Ronaldo Araújo SouzaJesus Djalma Pécora
Mar 8, 2008·International Journal of Cancer. Journal International Du Cancer·Mike VisserChris J L M Meijer
Apr 1, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nikolaos XenidisDimitris Mavroudis
Aug 13, 2009·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Junping XieHuanzhong Shi
Feb 26, 2011·International Journal of Cancer. Journal International Du Cancer·Jacques FerlayDonald Maxwell Parkin

❮ Previous
Next ❯

Citations

Apr 25, 2018·Scientific Reports·Jinlong JianYongxiang Shi

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
flow cytometry
FCS

Software Mentioned

SPSS

Related Concepts

Related Feeds

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.